MedTrace Logo

Evaluating the Glycemic Control wIth Vildagliptin and Metformin Combination Therapy.

NCT03577184 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2019-10-03

No results posted yet for this study

Summary

To evaluate the changes from baseline in random blood sugar (RBS) and fasting blood sugar (FBS) levels at week 12 in participants receiving Vildagliptin combination with Metformin.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Metformin/Vildagliptin

Vildagliptin belongs to dipeptidyl peptidase-4 (DPP-4) inhibitor. Inhibition of dipeptidyl peptidase-4 (DPP-4) and metformin is a Biguanides.

Sponsors & Collaborators

  • Clinision

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-31
Primary Completion
2018-12-31
Completion
2019-03-31
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03577184 on ClinicalTrials.gov